AstraZeneca’s “reduce” Rating Reaffirmed at Swedbank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “reduce” rating restated by stock analysts at Swedbank in a report issued on Thursday, Stock Ratings Network.com reports. They currently have a GBX 2,863.67 ($46.31) price objective on the stock. Swedbank’s price objective suggests a potential downside of 10.79% from the stock’s previous close.
AstraZeneca (LON:AZN) opened at 3218.00 on Thursday. AstraZeneca has a one year low of GBX 2786.00 and a one year high of GBX 3544.50. The stock has a 50-day moving average of GBX 3181.38 and a 200-day moving average of GBX 3261.42. The company’s market cap is £40.289 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America Corp. reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,200 ($51.75) price target on the stock. Separately, analysts at Nordea Equity Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Wednesday. They now have a GBX 3,877.70 ($62.71) price target on the stock. Twelve investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have assigned a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and a consensus price target of GBX 3,105.39 ($50.22).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.